Emcure to take full control of Gennova Biopharma with ₹232 crore stake acquisition
Emcure Pharmaceuticals is acquiring the remaining 12.05% stake in Gennova Biopharmaceuticals for ₹232 crore to gain full control. The move includes a leadership transition to focus on biologics and biosimilars.
Why it matters
Consolidating ownership in biotech subsidiaries is a strategic move for pharmaceutical companies to streamline R&D and focus on high-growth therapeutic areas.
Emcure Pharmaceuticals on Monday (July 13, 2026) said it is acquiring remaining 12.05% stake in subsidiary Gennova Biopharmaceuticals in a ₹232 crore deal.
Gennova, in which Emcure currently holds 87.95%, will become a wholly owned subsidiary on completion of the transaction as part of which the 12.05% minority stake held by founder Sanjay Singh and others is being acquired.
Besides the consolidation of its shareholding, Emcure also announced a leadership transition under which Samit Mehta will lead Gennova and sharpen focus on the biologics franchise, biosimilars development and adjacent therapeutic platforms, leveraging the established mammalian and microbial biomanufacturing platforms.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in